Insertion of Natural Intron 6a-6b into a Human cDNA-derived Gene Therapy Vector for Cystic Fibrosis Improves Plasmid Stability and Permits Facile RNA/DNA Discrimination

Journal of Gene Medicine

Volumn 1, Issue 5, 1999, Pages 312-321

  Boyd, A Christopher ^a   Popp, Friedrich ^b   Michaelis, Uwe ^c   Davidson, Heather ^a   Davidson Smith, Hazel ^a   Doherty, Ann ^a   McLachlan, Gerry ^d   Porteous, David J ^a   Seeber, Stefan ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c MBT Munich Biotechnology GmbH   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cystic fibrosis; Gene therapy vector; Insertion sequence; Intron; Plasmid stability; RT PCR

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

CFTR PROTEIN, HUMAN; COMPLEMENTARY DNA; MESSENGER RNA; PRIMER DNA; RNA; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINO ACID SEQUENCE; ARTICLE; COMPARATIVE STUDY; CYSTIC FIBROSIS; ESCHERICHIA COLI; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTRON; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; BASE SEQUENCE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA PRIMERS; DNA, COMPLEMENTARY; ESCHERICHIA COLI; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; INTRONS; MOLECULAR SEQUENCE DATA; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER;

EID: 0033182630     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(199909/10)1:5<312::aid-jgm55>3.0.co;2-%23     Document Type: Article

References (23)

1. Gregory RJ, Cheng SH, Rich DP, et al. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 1990; 347: 382-386.
2. Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene - cloning and characterization of complementary DNA. Science 1989; 245: 1066-1072.
3. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-634.
4. Yike I, Zhang Y, Ye J, Dearborn DG. Expression in Escherichia coli of cytoplasmic portions of the cystic fibrosis transmembrane conductance regulator: apparent bacterial toxicity of peptides containing R-domain sequences. Protein Expr Purif 1996; 7: 45-50.
5. Alton EWFW, Middleton PG, Caplen NJ, et al. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993; 5: 135-142.
6. McLachlan G, Davidson DJ, Stevenson BJ, et al. Evaluation in vitro and in vivo of cationic liposome expression construct complexes for cystic fibrosis gene therapy. Gene Ther 1995; 2: 614-622.
7. McLachlan G, Ho LP, Davidson-Smith H, et al. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther 1996; 3: 1113-1123.
8. Porteous DJ, Dorin JR, McLachlan G, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 210-218.
9. Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989.
10. Miller JH (ed). Experiments in Molecular Genetics. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1972.
11. Boyd AC, Porteous DJ. PCR-generated crossover linkers for site-directed mutagenesis. Biotechniques 1997; 23: 827-830.
12. Verkman AS, Sellers MC, Chao AC, Leung T, Ketcham R. Synthesis and characterization of improved chloride-sensitive fluorescent indicators for biological applications. Anal Biochem 1989; 178: 355-361.
13. West MR, Molloy CR. A microplate assay measuring chloride ion channel activity. Anal Biochem 1996; 241: 51-58.
14. Ohtsubo E, Sekine Y. Bacterial insertion sequences. Curr Top Microbiol Immunol 1996; 204: 1-26.
15. Korb M, Ke YB, Johnson LF. Stimulation of gene expression by introns - conversion of an inhibitory intron to a stimulatory intron by alteration of the splice donor sequence. Nucleic Acids Res 1993; 21: 5901-5908.
16. Culbertson MR. RNA surveillance - unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet 1999; 15: 74-80.
17. Hawley DK, McClure WR. Compilation and analysis of Escherichia coli promoter DNA sequences. Nucleic Acids Res 1983; 11: 2237-2255.
18. Whitsett JA, Dey CR, Stripp BR, et al. Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice. Nat Genet 1992; 2: 13-20.
19. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: Pitfalls and potential. Biotechniques 1999; 26: 112-125.
20. Thorpe PH, Porteous DJ. Rapid quantitation of gene therapy specific CFTR expression using the Amplification Refractory Mutation System. Biotechniques 1999; 27: 122-126.
21. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A 1991; 88: 478-482.
22. Choi T, Huang M, Gorman C, Jaenisch R. A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11: 3070-3074.
23. Clark AJ, Archibald AL, McClenaghan M, Simons JP, Wallace R, Whitelaw CBA. Enhancing the efficiency of transgene expression. Philos Trans R Soc Lond B Bio Sci 1993; 339: 225-232.